We will be comparing the differences between Verona Pharma plc (NASDAQ:VRNA) and Coherus BioSciences Inc. (NASDAQ:CHRS) as far as profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.
Valuation & Earnings Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Coherus BioSciences Inc. N/A 0.00 195.81M -3.13 0.00 Table 1 showcases the top-line revenue, earnings per share and valuation of Verona Pharma plc and Coherus BioSciences Inc.
Table 2 provides us Verona Pharma plc and Coherus BioSciences Inc.’s net margins, return on assets and return on equity.
Ratings and Recommendations for Verona Pharma plc and Coherus BioSciences Inc. can be find in next table.
Coherus BioSciences Inc. on the other hand boasts of a $28 average target price and a 87.42% potential upside.
Insider & Institutional Ownership
Institutional investors held 64.53% of Verona Pharma plc shares and 95.7% of Coherus BioSciences Inc. shares. Competitively, 0.1% are Coherus BioSciences Inc.’s share held by insiders.
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders. Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD) Verona Pharma plc -3.49% -10.97% -10.82% -34.55% -24.59% -11.13% Coherus BioSciences Inc. -10.04% -20.27% -44.41% -37.81% 17.75% 13.07% For the past year Verona Pharma plc had bearish trend while Coherus BioSciences Inc. had bullish trend.
Verona Pharma plc beats on 4 of the 7 factors Coherus BioSciences Inc.
Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The companyÂ’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma. Verona Pharma plc is based in London, the United Kingdom.
Coherus BioSciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. The companyÂ’s product candidates include CHS-1701, a pegfilgrastim biosimilar candidate, which is used for the treatment of febrile neutropenia; CHS-0214, an etanercept biosimilar candidate, which is in various phases of clinical trials for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis, and psoriasis; and CHS-5217, a bevacizumab biosimilar candidate, which is in preclinical stage for the treatment of metastatic colorectal cancer, nonÂ–small cell lung cancer, metastatic kidney cancer, advanced cervical cancer, platinum-resistant ovarian cancer, and recurrent glioblastoma. Its product candidates also comprise CHS-1420, an adalimumab biosimilar candidate, which is in various phases of clinical trials to treat ankylosing spondylitis, BehÃ§et’s Disease, CrohnÂ’s Disease, juvenile idiopathic arthritis, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis; and CHS-3351, a ranibizumab biosimilar candidate, which is in preclinical stage for the treatment of neovascular (wet) age-related macular, degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Coherus Biosciences, Inc. has license agreement with Daiichi Sankyo Company, Limited; Baxalta Incorporated, Baxalta US Inc., and Baxalta GmbH; Genentech, Inc.; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Click here to view original web page at Verona Pharma plc (VRNA)’s Financial Results Comparing With Coherus BioSciences Inc. (NASDAQ:CHRS)